Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.
Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.
Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the goals and importance of his company, Stack, during the NASP Annual Meeting in Washington, DC.
Top news of the week from Specialty Pharmacy Times.
Crizanlizumab-tmca (Adakveo, Novartis) is approved to reduce the frequency of vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.
Top news of the day from across the health care landscape.
Cefiderocol (Fetroja, Shionogi) is indicated for adults with complicated urinary tract infections, including kidney infections caused by Gram-negative pathogens, who have limited or no alternative treatment options.
Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for the treatment of mantle cell lymphoma in adults who have received at least 1 prior therapy.
Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC.
According to the affiliation agreement, the Institute for Safe Medication Practices will be an ECRI Institute subsidiary when the transaction closes in January, 2020.
In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.
Centers for Disease Control and Prevention warns the time for action is now in the "post-antibiotic era."
Receiving a flu shot before a heart bypass surgery can stop inflammation throughout the body and possibly lead to a healthier recovery, according to a preliminary study presented at the American Heart Association’s Scientific Sessions in Philadelphia, Pennsylvania.
The COAST-X study evaluated ixekizumab (Taltz, Eli Lilly) in patients with non-radiographic axial spondyloarthritis.
A study presented at the 2019 ACR/ARP Annual Meeting highlights the need for additional medications for the treatment of juvenile idiopathic arthritis in children.
With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.
The largest study of its kind has found that 40% of the European population carries a genetic variant that leads to antibody resistance against anti-tumor necrosis factor (TNF) drugs, infliximab and adalimumab, and lose response.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, was compared with a placebo in patients with ACS and persistent dyslipidemia, in addition to receiving treatment with high-intensity or maximum tolerated statin therapy.
A study reveals that axial psoriatic arthritis and ankylosing spondylitis with psoriasis are different diseases with different genetics, demographics, and disease expression.
Neither vitamin D nor omega-3 fatty acid supplementation were found to significantly inhibit changes in serum creatinine and cystatin C decline over 5 years among adults with type 2 diabetes.
The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab, as well as experts that pharmacists can contact with questions regarding buying, selling, and marketing.
A study conducted by the Uniting Medically Supervised Injecting Centre in Sydney, Australia found that intranasally administered naloxone can reverse opioid overdose, but not as efficiently as intramuscularly administered naloxone can.
Findings from a phase 3 study reinforced the safety and efficacy of rituximab (Rituxan, Genentech) as a treatment for patients with pemphigus vulgaris.
The injectable hormone tesamorelin was found to reduce liver fat and prevent liver fibrosis or scarring in people living with HIV, according to researchers and the National Institutes of Health and the National Institute of Allergy and Infectious Disease (NIAD).
Top news of the day from across the health care landscape.
A recent study published in CANCER indicates that for patients with both HIV and cancer, implementation of the Patient Protection and Affordable Care Act (ACA) improved insurance coverage, both in states that expanded Medicaid coverage and in states that did not.1
InsightRx, a company specializing in precision medicine, and Premier Inc, a health care improvement company, have partnered to individualize medication dosing for drugs used to treat infectious diseases.
Jesse C. Dresser, Esq explains how DIR fees affect specialty pharmacists at the NASP Annual Meeting in Washington, DC.
